Suicide genes: Past, present and future perspectives

Immunology Today

Volumn 21, Issue 1, 2000, Pages 48-54

  Lal, Shangara ^a   Lauer, Ulrich M ^a   Niethammer, Dietrich ^a   Beck, James F ^b   Schlegel, Paul G ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ADENOSINE DEAMINASE; ASIALOGLYCOPROTEIN RECEPTOR; CELL SURFACE RECEPTOR; CYTOSINE DEAMINASE; DEOXYCYTIDINE KINASE; DNA; DNA POLYMERASE; FLUOROURACIL; GANCICLOVIR; INTERLEUKIN 2; LIPOSOME; POLYLYSINE; STRUCTURAL PROTEIN; THYMIDINE KINASE; VIRUS GLYCOPROTEIN;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; BIOLOGICAL THERAPY; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENDOCYTOSIS; GENE TARGETING; GENE THERAPY; GENETIC TRANSFECTION; GRAFT VERSUS HOST REACTION; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; HYBRIDIZATION; LONG TERMINAL REPEAT; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; RAT; REVIEW; SUICIDE GENE; TARGET CELL;

ANIMALS; DISEASE MODELS, ANIMAL; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS;

EID: 0034130921     PISSN: 01675699     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5699(99)01550-9     Document Type: Review

References (47)

1. 1 Russel, S.J. (1993) Gene therapy for cancer. Cancer J. 6, 21-25
2. 2 Davis, B.M. et al. (1996) Current progress in the gene therapy of cancer. Curr. Opin. Oncol. 8, 499-508
3. 3 Verma, I.M. and Somia, N. (1997) Gene therapy - promises, problems and prospects. Nature 389, 239-242
4. 4 Farzin, F. et al. (1998) Gene therapy of cancer. Immunol. Today 19, 294-296
5. 5 Cohen, J.L. et al. (1999) Would suicide gene therapy solve the 'T-cell dilemma' of allogeneic bone marrow transplantation? Immunol. Today 20, 172-176
6. 6 Wolff, J.A., ed. (1994) Gene Therapeutics (1st edn), Birkhauser
7. 7 Robbins, P.D., ed. (1997) Gene Therapy Protocols (1st edn), Humana Press
8. 8 Goff, S.P. and Berg, P. (1976) Construction of hybrid viruses containing SV40 and λ phage DNA segments and their propagation in cultured monkey cells. Cell 9, 695-705
9. 9 Shimotohno, K. and Temin, H.M. (1981) Formation of infectious progeny virus after insertion of herpes simplex thymidine kinase gene into DNA of an avian retrovirus. Cell 26, 67-77
10. 10 Wei, C-M. et al. (1981) Construction and isolation of a transmissible retrovirus containing the src gene of Harvey murine sarcoma virus and the thymidine kinase gene of herpes simplex virus type 1. J. Virol. 39, 935-944
11. 11 Tabin, C.J. et al. (1982) Adaptation of a retrovirus as a eukaryotic vector transmitting the herpes simplex virus thymidine kinase gene. Mol. Cell. Biol. 2, 426-436
12. 12 Ferry, N. et al. (1991) Retroviral-mediated gene transfer into hepatocytes in vivo. Proc. Natl. Acad. Sci. U. S. A. 88, 8377-8381
13. 13 Stratford-Perricaudet, L.D. et al. (1990) Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector. Hum. Gene Ther. 1, 241-256
14. 14 Culver, K.W. et al. (1992) In vivo gene transfer with vector-producer cells for treatment of experimental brain tumors. Science 256, 1550-1552
15. 15 Snyder, R.O. et al. (1997) Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat. Genet. 16, 270-276
16. 16 Blömer, U. et al. (1997) Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J. Virol. 71, 6641-6649
17. 17 Reiprich, S. et al. (1997) Replication-competent chimeric lentioncovirus with expanded host cell tropism. J. Virol. 71, 3328-3331
18. 18 Poeschla, E.M. et al. (1998) Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nat. Med. 4, 354-357
19. 19 Aposhian, H.V. et al. (1972) Polyoma pseudovirions: an experimental model for the development of DNA for gene therapy. Fed. Proc. 31, 1310-1325
20. 20 Moss, B. et al. (1996) Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc. Natl. Acad. Sci. U. S. A. 93, 11341-11348
21. 21 Berglund, P. et al. (1993) Semliki Forest virus expression system: production of conditionally infectious recombinant particles. Biotechnology 11, 916-920
22. 22 Leyrer, S. et al. (1998) Sendai virus-like particles devoid of haemagglutinin-neuraminidase protein infect cells via the human asialoglycoprotein receptor. J. Gen. Virol. 79, 683-687
23. 23 Mann, R. et al. (1983) Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell 33, 153-159
24. 24 Graham, F.L. et al. (1977) Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36, 59-72
25. 25 Wu, G.Y. et al. (1991) Receptor-mediated gene delivery in vivo. Partial correction of genetic analbuminemia in Nagase rats. J. Biol. Chem. 266, 14338-14342
26. 26 Curiel, D.T. et al. (1991) Adenovirus enhancement of transferrin-polylysine-mediated gene delivery. Proc. Natl. Acad. Sci. U. S. A. 88, 8850-8854
27. 27 Curiel, D.T. et al. (1992) High-efficiency gene transfer mediated by adenovirus coupled to DNA-polylysine complexes. Hum. Gene Ther. 3, 147-154
28. 28 Chen, H.H. et al. (1997) Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc. Natl. Acad. Sci. U. S. A. 94, 1645-1650
29. 29 Burns, J.C. et al. (1993) Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to a very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci. U. S. A. 90, 8033-8037
30. 30 Spiegel, M. et al. (1998) Pseudotype formation of Moloney murine leukemia virus with Sendai virus glycoprotein F, J. Virol. 72, 5296-5302
31. 31 Wybranietz, W.A. et al. (1999) Quantification of VP22-GFP spread by direct fluorescence in 15 commonly used cell lines. J. Gene Med. 1, 265-274
32. 32 Heyman, R.A. et al. (1989) Thymidine kinase obliteration: creation of transgenic mice with controlled immune deficiency. Proc. Natl. Acad. Sci. U. S. A. 86, 2698-2702
33. 33 Mullen, C.A. et al. (1992) Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc. Natl. Acad. Sci. U. S. A. 89, 33-37
34. 34 Austin, E.A. and Huber, B.E. (1992) A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing, and expression of Escherichia coli cytosine deaminase. Mol. Pharmacol. 43, 380-387
35. 35 Hapke, D.M. et al. (1996) Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity. Cancer Res. 56, 2343-2347
36. 36 Chen, L. et al. (1996) Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene. Cancer Res. 56, 1331-1340
37. 37 Nishiyama, T. et al. (1985) Antineoplastic effects in rats of 5-fluorocytosine in combination with cytosine deaminase capsules. Cancer Res. 45, 1753-1761
38. 38 Phelan, A. et al. (1998) Intercellular delivery of functional p53 by the herpesvirus protein VP22. Nat. Biotechnol. 16, 440-443
39. 39 Chen, S.H. et al. (1995) Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc. Natl. Acad. Sci. U. S. A. 92, 2577-2581
40. 40 O'Malley, B.W.J. et al. (1996) Combination gene therapy for oral cancer in a murine model. Cancer Res. 56, 1737-1741
41. 41 Mullen, C.A. et al. (1994) Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. Cancer Res. 54, 1503-1506
42. 42 Santodonato, L. et al. (1996) Cure of mice with established metastatic friend leukemia cell tumors by a combined therapy with tumor cells expressing both interferon-α1 and herpes simplex thymidine kinase followed by ganciclovir. Hum. Gene Ther. 7, 1-10
43. 43 Nanakorn, T. et al. (1997) Cytosine deaminase adenoviral vector system reduces levels of contaminating breast cancer cells admixed with a thousand fold excess of hematopoietic cells by up to 500,000 fold following exposure to 5-fluorocytosine, which is converted to 5-fluorouracil by this system selectively in the breast cancer cells. Blood 90 (Suppl. 1), 555a
44. 44 Freeman, S.M. et al. (1995) Treatment of ovarian cancer using a gene-modified vaccine. Hum. Gene Ther. 6, 927-939
45. 45 Bordignon, C. et al. (1995) Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation. Hum. Gene Ther. 6, 813-819
46. 46 Bonini, C. et al. (1997) HSV-tk gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276, 1719-1724
47. 47 Freeman, S.M. et al. (1996) In situ use of suicide genes for cancer therapy. Semin. Oncol. 23, 31-45